Onkologie. 2024:18(2):130-136 | DOI: 10.36290/xon.2024.024

Hepatocellular carcinoma - systemic treatment in 2024

Marián Liberko, Renata Soumarová
Onkologická klinika, FNKV a 3. LF UK, Praha
3. lékařská fakulta Univerzity Karlovy, Praha

After years of stagnation since the introduction of sorafenib, the treatment options for hepatocellular carcinoma have expanded significantly, especially in recent years. There are now several first-line treatment options (sorafenib, lenvatinib, atezolizumab + bevacizumab, tremelimumab + durvalumab) as well as more options in second-line treatment (regorafenib, cabozantinib, ramucirumab, pembrolizumab). Immunotherapy is increasingly making its way into the treatment of patients with hepatocellular carcinoma. This article aims to provide an overview of the current treatment options for this disease with a focus on the treatment of advanced stages in first and second line systemic therapy.

Keywords: hepatocellular carcinoma, targeted therapy, immunotherapy.

Accepted: April 19, 2024; Published: May 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Hepatocellular carcinoma - systemic treatment in 2024. Onkologie. 2024;18(2):130-136. doi: 10.36290/xon.2024.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. Go to original source... Go to PubMed...
    2. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308. Erratum in: Ann Oncol. 2019 May 1;30(5):871-873. Erratum in: Ann Oncol. 2022;33(6):666. PMID: 30285213. Go to original source... Go to PubMed...
    3. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. PMID: 34801630; PMCID: PMC8866082. Go to original source... Go to PubMed...
    4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. doi: 10.1056/NEJMoa0708857. PMID: 18650514. Go to original source... Go to PubMed...
    5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1): 25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. PMID: 19095497. Go to original source... Go to PubMed...
    6. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850. Go to original source... Go to PubMed...
    7. Kudo M, Finn RS, Qin S, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). Journal of Clinical Oncology 37, no. 4_suppl (February 01, 2019) 186-186. doi: 10.1200/JCO.2019.37.4_suppl.186. Go to original source...
    8. Roland CL, Dineen SP, Lynn KD, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009;8(7):1761-1771. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30. PMID: 19567820. Go to original source... Go to PubMed...
    9. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139-148. doi: 10.1084/jem.20140559. Epub 2015 Jan 19. PMID: 25601652; PMCID: PMC4322048. Go to original source... Go to PubMed...
    10. Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. doi: 10.1038/ncomms12624. PMID: 27571927; PMCID: PMC5013615. Go to original source... Go to PubMed...
    11. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117-124. doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8. PMID: 29229461. Go to original source... Go to PubMed...
    12. Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. Erratum in: Lancet Oncol. 2020 Jul;21(7):e341. PMID: 32502443. Go to original source... Go to PubMed...
    13. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160. Go to original source... Go to PubMed...
    14. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11. PMID: 34902530. Go to original source... Go to PubMed...
    15. Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. PMID: 34292792; PMCID: PMC8445563. Go to original source... Go to PubMed...
    16. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1(8):EVIDoa2100070). Go to original source... Go to PubMed...
    17. Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8. doi: 10.1016/j.annonc.2024.02.005. Epub ahead of print. PMID: 38382875. Go to original source... Go to PubMed...
    18. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. PMID: 34914889. Go to original source... Go to PubMed...
    19. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003. PMID: 37796513; PMCID: PMC10557031. Go to original source... Go to PubMed...
    20. Verset G, Borbath I, Karwal M, et al. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807. PMID: 35421228; PMCID: PMC9784157. Go to original source... Go to PubMed...
    21. Ivan Borbath, Laethem JL van, Karwal M, et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study. JCO 40, 4109-4109(2022). doi:10.1200/JCO.2022.40.16_suppl.4109. Go to original source...
    22. Finn RS, Ikeda M, Zhu AX. Et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. PMID: 32716739; PMCID: PMC7479760. Go to original source... Go to PubMed...
    23. Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. PMID: 38039993. Go to original source... Go to PubMed...
    24. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. PMID: 35798016. Go to original source... Go to PubMed...
    25. Yau T, Kaseb A, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024:S2468-1253(23)00454-5. doi: 10.1016/S2468-1253(23)00454-5. Epub ahead of print. PMID: 38364832. Go to original source... Go to PubMed...
    26. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54-63. doi: 10.1056/NEJMoa1717002. PMID: 29972759; PMCID: PMC7523244. Go to original source... Go to PubMed...
    27. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. PMID: 35798016. Go to original source... Go to PubMed...
    28. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treat­ment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017;389(10064):36. PMID: 27932229. Go to original source... Go to PubMed...
    29. Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. PMID: 26095784. Go to original source... Go to PubMed...
    30. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. PMID: 30665869. Go to original source... Go to PubMed...
    31. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018;19(9):e440. PMID: 29875066. Go to original source... Go to PubMed...
    32. Kudo M, Finn RS, Edeline J, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022;167:1-12. doi: 10.1016/j.ejca.2022.02.009. Epub 2022 Mar 29. PMID: 35364421. Go to original source... Go to PubMed...
    33. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. PMID: 31790344. Go to original source... Go to PubMed...
    34. Merle P, Kudo M, Edeline J, et al. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer. 2023;12(4):309-320. doi: 10.1159/000529636. PMID: 37901200; PMCID: PMC10601873. Go to original source... Go to PubMed...
    35. Qin S, Chen Z, Fang W, et al. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2023;41(7):1434-1443. doi: 10.1200/JCO.22.00620. Epub 2022 Dec 1. PMID: 36455168; PMCID: PMC9995104. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.